An Ionis Pharmaceuticals drug in development for Angelman syndrome has mid-stage clinical trial results showing improvement across a range of measures of this rare neurodevelopmental disorder, and the ...
Ionis Pharmaceuticals’ investigational treatment for hereditary angioedema (HAE) has hit the primary endpoint of a phase 3 trial, allowing the biotech to ready its approval application to the FDA. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results